Cash and cash equivalents [USD, thousands]

Marketable securities, available-for-sale [USD, thousands]

Accounts receivable, net and contract assets [USD, thousands]

Inventories [USD, thousands]

Prepaid expenses and other current assets [USD, thousands]

Total current assets [USD, thousands]

Property and equipment, net [USD, thousands]

Prepaid expenses and other assets [USD, thousands]

Goodwill [USD, thousands]

Intangible assets, net [USD, thousands]

Deferred tax assets, net [USD, thousands]

Total assets [USD, thousands]

Accounts payable [USD, thousands]

Accrued expenses [USD, thousands]

Total current liabilities [USD, thousands]

Long-term debt, net [USD, thousands]

Other long-term liabilities [USD, thousands]

Total liabilities [USD, thousands]

Common stock - amount [USD, thousands]

Additional paid-in capital [USD, thousands]

Accumulated other comprehensive income (loss) [USD, thousands]

Retained earnings [USD, thousands]

Total stockholders’ equity [USD, thousands]

Total liabilities and stockholders’ equity [USD, thousands]

4b52ceaa154ab6d36d0b51b0d1bdb6d25270c51c9301d6457fe3b2e95b93e742

Royalties (USD, thousands)

Product Sales, Net (USD, thousands)

Revenues Under Collaborative Agreements (USD, thousands)

Total Revenues (USD, thousands)

Cost of Sales (USD, thousands)

Amortization of Intangibles (USD, thousands)

Research and Development (USD, thousands)

Selling, General and Administrative (USD, thousands)

Total Operating Expenses (USD, thousands)

Operating Income (USD, thousands)

Investment and Other Income, Net (USD, thousands)

Interest Expense (USD, thousands)

Income Before Income Tax Expense (USD, thousands)

Income Tax Expense (USD, thousands)

Net Income (USD, thousands)

Earnings per Share, Basic (USD)

Earnings per Share, Diluted (USD)

Weighted Average Common Shares Outstanding, Basic (thousands)

Weighted Average Common Shares Outstanding, Diluted (thousands)

5850fbcfd2d3c58a376315d0070687bf13f3cfb95c1b7d15c2ac7397ad2a43bf

Net Income [USD, thousands]

Share-based Compensation [USD, thousands]

Depreciation and Amortization [USD, thousands]

Amortization of Intangible Assets [USD, thousands]

Amortization of Debt Discount [USD, thousands]

Accretion of (Premium) Discount on Marketable Securities, Net [USD, thousands]

Realized Gain (Loss) on Marketable Securities [USD, thousands]

Lease Payments Recognized (Deferred) [USD, thousands]

Net Cash Provided by Operating Activities [USD, thousands]

Purchases of Marketable Securities [USD, thousands]

Proceeds from Sales and Maturities of Marketable Securities [USD, thousands]

Purchases of Property and Equipment [USD, thousands]

Net Cash Used in Investing Activities [USD, thousands]

Taxes Paid Related to Net Share Settlement, Net of Proceeds from Issuance of Common Stock under Equity Incentive Plans [USD, thousands]

Net Cash (Used in) Provided by Financing Activities [USD, thousands]

Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Deferred Income Taxes [USD, thousands]

Accounts Receivable, Net and Other Contract Assets [USD, thousands]

Prepaid Expenses and Other Assets [USD, thousands]

Accounts Payable and Accrued Expenses [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at Beginning of Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at End of Period [USD, thousands]

06c0e43f0bb853c0dad3da35c8205f24af2f6e94b89f49f6ef8b568cc20e46bb

Number of total ENHANZE commercial products (products)

Number of ENHANZE commercial products from Roche (products)

Number of ENHANZE commercial products from Takeda (products)

Number of ENHANZE commercial products from Janssen (products)

Number of ENHANZE commercial products from argenx (products)

Number of ENHANZE commercial products from BMS (products)

2f7af90bf822c7c8849cd21028431e0dc1efa3116acba89be5cdd0d269377cb5

United States

Switzerland

Belgium

Japan

All Other Foreign

Total Revenue

e9b5d74ac5068eabec123480c76fa44bf77ffe2c3a3ac98e5bd9ca0e39708836

Royalties

Product Sales, Net

- Proprietary Product Sales

- Bulk rHuPH20 Sales

- Device Partnered Product Sales

Revenues Under Collaborative Agreements

- Upfront License and Target Nomination Fees

- Event-Based Development and Regulatory Milestones

- Sales-Based Milestones

- Device Licensing and Development Revenue

665b49f083713dee27700ce9d0fabda434d67086b7b65af3657bda317ebd6e00

HALOZYME THERAPEUTICS (HALO)

Financials